Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSL considers stoppers "more suitable for thimerosal-containing products"

This article was originally published in Scrip

Executive Summary

CSL is investigating the use of alternative stoppers "more suitable to thimerosal-containing products" for use with its multi-dose vials (MDV) of vaccines containing the preservative, in the wake of a recent letter from the US FDA citing GMP concerns. The company told Scrip that it was "working diligently" to address the issues raised by the agency, but noted that it had been "using the MDV stoppers for several years without negative impact".



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts